Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Clinical Trial

Official title:
A Pilot Study of Anlotinib for the Evaluation of Safety and Efficacy in Patients With Stage IV Natural Killer/T-cell Lymphoma and Refractory to L-asparaginase Based Chemotherapy

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of anlotinib in patients with stage IV extranodal natural killer/T-cell lymphoma, nasal type.

Clinical Trial Description

Extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, is a rare subtype of non-Hodgkin lymphoma (NHL) with relatively high incidence in China. L-asparaginase based chemotherapy improved overall response and prolonged the long-term survival for patients with stage IV. But the treatment for the patients with advanced disease and resistant to L-asparaginase based chemotherapy has not been established. The overall survival for these patients are very poor. This study is designed to evaluate the efficacy and safety of anlotinib in patients with stage IV ENKTCL and refractory to L-asparaginase based chemotherapy. ;

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, T-Cell
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Clinical Trial Details

NCT number	NCT03618238
Study type	Interventional
Source	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status	Completed
Phase	Phase 2
Start date	July 25, 2018
Completion date	April 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05058755` - Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma	N/A
Recruiting	`NCT06314334` - Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma	Phase 2
Recruiting	`NCT04004572` - Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma	Phase 2
Recruiting	`NCT03623087` - SIMPLE Chemotherapy for NK Lymphoma/Leukaemia	Phase 3
Recruiting	`NCT03107962` - Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma	Phase 2
Recruiting	`NCT03630731` - Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma	Phase 2
Completed	`NCT03936452` - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma	Phase 2
Recruiting	`NCT04366128` - Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL	N/A
Recruiting	`NCT06376721` - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma	Phase 1/Phase 2